Polyethylene glycol modification of filgrastim results in decreased renal clearance of the protein in rats.
about
Phase II, randomized, open-label study of pegfilgrastim-supported VDC/IE chemotherapy in pediatric sarcoma patientsG-CSF and GM-CSF in NeutropeniaDesign Rationale and Development Approach for Pegfilgrastim as a Long-Acting Granulocyte Colony-Stimulating FactorA combined model of human erythropoiesis and granulopoiesis under growth factor and chemotherapy treatment.From stealthy polymersomes and filomicelles to "self" Peptide-nanoparticles for cancer therapyNoninvasive detection of passively targeted poly(ethylene glycol) nanocarriers in tumors.Profile of peginesatide and its potential for the treatment of anemia in adults with chronic kidney disease who are on dialysis.Pegfilgrastim: evidence in support of its use with cytotoxic chemotherapy.Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action.Pharmacokinetic and -dynamic modelling of G-CSF derivatives in humans.MicroRNA-378 limits activation of hepatic stellate cells and liver fibrosis by suppressing Gli3 expression.Managing dialysis patients who develop anemia caused by chronic kidney disease: focus on peginesatide.Effectiveness of cytopenia prophylaxis for different filgrastim and pegfilgrastim schedules in a chemotherapy mouse model.Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas.Development of biosimilars--pharmacokinetic and pharmacodynamic considerations.Pharmacokinetics and pharmacodynamics of pegfilgrastim.Prevention of chemotherapy-induced neutropenia with pegfilgrastim: pharmacokinetics and patient outcomes.Early engineering approaches to improve peptide developability and manufacturability.Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors.Therapeutic l-asparaginase: upstream, downstream and beyond.G-CSF/anti-G-CSF antibody complexes drive the potent recovery and expansion of CD11b+Gr-1+ myeloid cells without compromising CD8+ T cell immune responsesSerum pegfilgrastim concentrations during recovery of absolute neutrophil count in patients with cancer receiving pegfilgrastim after chemotherapy.Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects.Relationship between absolute neutrophil count profiles and pharmacokinetics of DA-3031, a pegylated granulocyte colony-stimulating factor (pegylated-G-CSF): a dose block-randomized, double-blind, dose-escalation study in healthy subjects.Pharmacokinetic and pharmacodynamic properties of a new long-acting granulocyte colony-stimulating factor (HM10460A) in healthy volunteers.Exploring the amphiphilicity of PEGylated gold nanorods: mechanical phase transfer and self-assembly.Model-based optimization of G-CSF treatment during cytotoxic chemotherapy.Model-based approach to describe G-CSF effects in carboplatin-treated cancer patients.
P2860
Q24632145-D3152209-D6BD-4382-9B2F-1520F3DDFF4BQ26800954-9BBEA103-7596-4D0E-B1E1-CA1C126153AEQ27004054-D5E69CEE-2DB2-4DB7-B540-F6F3E9590967Q33712928-E3929937-87FB-4A6B-9232-3492259E1E26Q35295381-96328994-F085-4F9F-A8E0-148AF5C51191Q35671286-0572B392-52C3-4CE1-AB52-E93FD0C72935Q36039649-BBA5B61E-2C0B-4151-A396-5F7FDF269A7AQ36235531-919D057C-E47B-4901-A72A-6E3EF1FD518CQ36327074-A08A1237-7F81-4610-997A-3FF9EFA63565Q36427261-4EF76464-1BCB-4FF2-A0E6-64B48D743D58Q36719130-3FD0C22E-DF3F-4938-8987-8207CA294ABFQ37157237-D798F9DA-1A14-48A6-8852-2E162024539FQ37303210-82B3F444-5D27-4036-A5A2-ABEBD35673DAQ37455829-03130BCA-2904-4706-BF85-7DBF72281E27Q37676066-982F429C-A1F7-4EE5-A174-A8B1746E17C7Q37860299-27669211-C565-4CFF-9289-DCBF7200A85FQ38072290-C3915FBE-CA77-487C-940A-247E0D42C827Q38262021-862FC541-6C80-4743-B901-8FBC3321016AQ38613025-34067DBA-9A80-4CD2-AA3D-66ABBC092978Q38676439-8F4EDD5C-8167-46E9-9259-A03316A64C82Q41956513-CA7096B3-EA01-4B23-A8FE-9853302650D6Q42632652-1C3B8250-CFEF-44B5-829E-61FCF12C67D0Q42689963-1B0D5C93-7E3E-400A-9FBD-10C9B6D53009Q44019603-AB1B3DAD-9F11-448A-9DF5-1DD56EEF2B56Q44555003-EAEF1F6C-9CB6-4612-84DE-3EEFB48B58C1Q46770408-A2C7A581-AEAE-4EF7-8B88-CAD7CE90BE8CQ47657705-60811F7C-8CD2-42F9-836E-4FD90FCE5049Q50878372-EA68C8F7-2B7F-4EB1-A58C-D57702B93E6E
P2860
Polyethylene glycol modification of filgrastim results in decreased renal clearance of the protein in rats.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Polyethylene glycol modificati ...... arance of the protein in rats.
@en
Polyethylene glycol modificati ...... arance of the protein in rats.
@nl
type
label
Polyethylene glycol modificati ...... arance of the protein in rats.
@en
Polyethylene glycol modificati ...... arance of the protein in rats.
@nl
prefLabel
Polyethylene glycol modificati ...... arance of the protein in rats.
@en
Polyethylene glycol modificati ...... arance of the protein in rats.
@nl
P2093
P356
P1476
Polyethylene glycol modificati ...... arance of the protein in rats.
@en
P2093
Bing-Bing Yang
Lorin K Roskos
Michael M Hayashi
Peggy K Lum
P304
P356
10.1002/JPS.20024
P407
P577
2004-05-01T00:00:00Z